Cardiovascular Events in Chronic Dialysis Patients: Emphasizing the Importance of Vascular Disease Prevention

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2010 Jun 25

PMID 20574691

Citations 10

Authors

Kosmas I Paraskevas

Ioannis Kotsikoris

Sotirios A Koupidis

Alexandros A Tzovaras

Dimitri P Mikhailidis

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease is the leading cause of death in both chronic kidney disease and peritoneal dialysis/hemodialysis patients. Vascular disease prevention in these patients is therefore important to reduce the incidence of cardiovascular events and the high morbidity and mortality. This Editorial discusses the traditional, (1) smoking, (2) dyslipidemia, (3) body mass index, (4) glycemic control and (5) blood pressure, and non-traditional, (1) anemia, (2) vitamin D/hyperparathyroidism, (3) calcium/phosphorus metabolism and (4) magnesium, risk factors in renal patients. Current evidence does not support routine statin use and antiplatelet medication to dialysis patients. Patient compliance and adherence to proposed measures could be essential to reduce cardiovascular events and mortality rates in this high-risk population.

Citing Articles

Implications of advanced oxidation protein products and vitamin E in atherosclerosis progression.

Toualbi L, Mounir A, Wafa B, Medina A, Abderrezak K, Chahine T Arch Med Sci Atheroscler Dis. 2021; 6:e135-e144.

PMID: 34381915 PMC: 8336440. DOI: 10.5114/amsad.2021.107823.

Oxidative stress accelerates the carotid atherosclerosis process in patients with chronic kidney disease.

Toualbi L, Adnane M, Abderrezak K, Ballouti W, Arab M, Toualbi C Arch Med Sci Atheroscler Dis. 2020; 5:e245-e254.

PMID: 33305063 PMC: 7717441. DOI: 10.5114/amsad.2020.98945.

Prognostic performance of combined use of high-sensitivity troponin T and creatine kinase MB isoenzyme in high cardiovascular risk patients with end-stage renal disease.

Ahmed K, Al-Attab W Kidney Res Clin Pract. 2017; 36(4):358-367.

PMID: 29285428 PMC: 5743045. DOI: 10.23876/j.krcp.2017.36.4.358.

Association of adiponectin with peripheral arterial disease and mortality in nondiabetic hemodialysis patients: Long-term follow-up data of 7 years.

Zhou Y, Zhang J, Zhang W, Ni Z J Res Med Sci. 2016; 21:50.

PMID: 27904596 PMC: 5121992. DOI: 10.4103/1735-1995.184000.

Twenty four-hour ambulatory blood pressure monitoring and lipid levels before, 3, 6 and 12 months after the onset of hemodialysis in chronic kidney disease patients: a pilot study.

Vagiona A, Koupidis S, Passadakis P, Thodis E, Vargemezis V Hippokratia. 2013; 16(2):154-8.

PMID: 23935271 PMC: 3738417.

References

Shoben A, Rudser K, de Boer I, Young B, Kestenbaum B . Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008; 19(8):1613-9. PMC: 2488261. DOI: 10.1681/ASN.2007111164. View

Bradbury B, Fissell R, Albert J, Anthony M, Critchlow C, Pisoni R . Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol. 2007; 2(1):89-99. DOI: 10.2215/CJN.01170905. View

Ganesh S, Stack A, Levin N, Hulbert-Shearon T, Port F . Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12(10):2131-2138. DOI: 10.1681/ASN.V12102131. View

Hirachan P, Thijssen S, Levin N, Kotanko P . Body composition and outcomes in chronic hemodialysis patients. Contrib Nephrol. 2008; 161:108-114. DOI: 10.1159/000130422. View

Meyer K, Levey A . Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease. J Am Soc Nephrol. 2001; 9(12 Suppl):S31-42. View

Turgut F, Kanbay M, Metin M, Uz E, Akcay A, Covic A . Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol. 2008; 40(4):1075-82. DOI: 10.1007/s11255-008-9410-3. View

Kanbay M, Goldsmith D, Erkmen Uyar M, Turgut F, Covic A . Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif. 2010; 29(3):280-92. DOI: 10.1159/000276665. View

Soran H, Durrington P . Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother. 2008; 9(12):2145-60. DOI: 10.1517/14656566.9.12.2145. View

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

10.

Dimkovic N, Oreopoulos D . Assisted peritoneal dialysis as a method of choice for elderly with end-stage renal disease. Int Urol Nephrol. 2008; 40(4):1143-50. DOI: 10.1007/s11255-008-9427-7. View

11.

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

12.

Deferrari G, Ravera M, Berruti V, Leoncini G, Deferrari L . Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. J Am Soc Nephrol. 2003; 15 Suppl 1:S6-S11. DOI: 10.1097/01.asn.0000105881.71167.44. View

13.

Hsiao F, Huang W, Wen Y, Chen P, Kuo K, Tsai Y . Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 2009; 32(8):675-90. DOI: 10.2165/00002018-200932080-00006. View

14.

Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

15.

Tziomalos K, Athyros V, Karagiannis A, Mikhailidis D . Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem. 2009; 9(14):1291-7. DOI: 10.2174/156802609789869628. View

16.

Perry R, Griffiths W, Dextraze P, Solomon R, Trebbin W . Elevated nicotine levels in patients undergoing hemodialysis. A role in cardiovascular mortality and morbidity?. Am J Med. 1984; 76(2):241-6. DOI: 10.1016/0002-9343(84)90780-0. View

17.

Koch M, Trapp R, Kulas W, Grabensee B . Critical limb ischaemia as a main cause of death in patients with end-stage renal disease: a single-centre study. Nephrol Dial Transplant. 2004; 19(10):2547-52. DOI: 10.1093/ndt/gfh404. View

18.

London G, Guerin A, Marchais S, Metivier F, Pannier B, Adda H . Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18(9):1731-40. DOI: 10.1093/ndt/gfg414. View

19.

Lacson Jr E, Lazarus J . The association between blood pressure and mortality in ESRD-not different from the general population?. Semin Dial. 2007; 20(6):510-7. DOI: 10.1111/j.1525-139X.2007.00339.x. View

20.

Foley R, Parfrey P, Sarnak M . Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 2001; 9(12 Suppl):S16-23. View